Sage Therapeutics said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 ...

After a year of disappointing drug trial results, Sage Therapeutics Inc. is slashing its headcount and shaking up its ...

Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...

On Thursday, Sage Therapeutics, Inc. (NASDAQ:SAGE) announced a strategic reorganization of its business operations to support ...

Sage Therapeutics announces a reorganization to support product launch and pipeline development, resulting in a workforce ...

Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich ...

Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating on October 10. Ami Fadia’s rating is ...

Sage and Biogen last year won Food and Drug Administration approval of Zurzuvae as the first pill to treat postpartum depression, but the agency rejected the drug for major depressive disorder, a much ...

Sage said in an SEC filing that it expects a non-recurring charge tied to the workforce reduction of $26 million to $28 ...

The biopharmaceutical company says the reorganization is meant to strengthen its balance sheet and position it for long-term ...

Sage plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s after it failed to boost cognitive function in a Phase 2 ...

Pomerantz LLP announces that a class action lawsuit has been filed against EngageSmart, Inc. ("EngageSmart" or the "Company") . Such investors are advised to contact Danielle Peyton at ...